Evidence map›Paper›PMID 40778857›Full record

ArticleThe Journal of cell biology2025

Dominant-negative isoform of TDP-43 is regulated by ALS-linked RNA-binding proteins.

Minami Hasegawa-Ogawa, Asako Onda-Ohto, Takumasa Nakajo, Arisa Funabashi, Ayane Ohya, Ryota Yazaki, Hirotaka James Okano

Abstract read
In one paragraph

Article in The Journal of cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  2. Article
  3. Review
  4. From development to disease: the neuronal role of hnRNPs through the lens ofFrontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Minami Hasegawa-OgawaDivision of Regenerative Medicine, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0009-0002-9221-1763
Asako Onda-OhtoDivision of Regenerative Medicine, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0009-0006-3201-5575
Takumasa NakajoDivision of Regenerative Medicine, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0009-0002-2640-3070
Arisa FunabashiDivision of Regenerative Medicine, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0009-0008-2673-0833
Ayane OhyaDivision of Regenerative Medicine, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0009-0006-9743-2572
Ryota YazakiDivision of Regenerative Medicine, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0009-0009-9860-7815
Hirotaka James OkanoDivision of Regenerative Medicine, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0000-0003-4611-7098

Funding

Japan Society for the Promotion of Science JP16H07218Japan Society for the Promotion of Science JP17K09766Japan Society for the Promotion of Science JP17K14967Japan Society for the Promotion of Science JP20K15904Japan Society for the Promotion of Science JP21K07302Japan Society for the Promotion of Science JP23K06812Jikei University Graduate Research FundJikei University School of MedicineUehara Memorial Foundation
6 · The paper itself

Abstract

TDP-43, an RNA-binding protein (RBP) encoded by the TARDBP gene, is crucial for understanding the pathogenesis of neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration. Dysregulated TDP-43 causes motor neuron loss, highlighting the need for proper expression levels. Here, we identify a dominant-negative isoform among the multiple TARDBP splicing variants and validate its endogenous expression using a developed antibody against its translated product. Furthermore, we revealed that ALS-associated RBPs regulate its expression: hnRNP K promotes its splicing and expression, while hnRNP A1 and FUS suppress these processes through distinct mechanisms. hnRNP A1 inhibits hnRNP K-mediated splicing, and FUS represses the dominant-negative isoform through both its translational inhibition and hnRNP K suppression. Notably, ALS-mutant FUS weakens this regulatory mechanism, leading to impaired repression of hnRNP K and the dominant-negative isoform. Our findings suggest a regulatory network involving ALS-linked RBPs that govern TDP-43 isoform expression and provide new insights into how disruptions in this network contribute to ALS pathogenesis.

Indexed as

Amyotrophic Lateral SclerosisDNA-Binding ProteinsRNA-Binding Protein FUSRNA-Binding ProteinsAlternative SplicingAnimalsHEK293 CellsHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein Group A-BHeterogeneous-Nuclear Ribonucleoprotein KHumansProtein IsoformsDNA-Binding ProteinsFUS protein, humanHeterogeneous Nuclear Ribonucleoprotein A1Heterogeneous-Nuclear Ribonucleoprotein Group A-BHeterogeneous-Nuclear Ribonucleoprotein KhnRNPA1 protein, humanHNRNPK protein, humanProtein IsoformsRNA-Binding Protein FUSRNA-Binding ProteinsTARDBP protein, human

Identifiers

PMID40778857
PMCPMC12333503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.